Pharma & Biotech Global Week in Review 23 December 2009 from IP Think Tank

Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/

 
Highlights this week included:

Zyprexa (Olanzapine) – UK: Court of Appeal upholds Justice Floyd’s decision finding Olanzapine patent valid: Dr Reddy’s Laboratories v Eli Lilly (EPLAW) (IPKat) (Managing IP) (PatLit) (GenericsWeb)

France: Pharma trade marks under threat – Senate and National Assembly approve law that would allow generic companies to copy shape and colour of branded pharmaceuticals (Managing IP)

 
General

WTO extends deadline for health IP amendment acceptance – TRIPS (IP Watch)

Patent cliffs and lessons from 60 years old pharmaceutical innovation (ipeg)

Paediatric extensions: a major article – Fostering paediatric research and the right to extend supplementary protection certificates (SPC blog)

Brazil: Are seeds really computer chips?: Proposed amendments to Plant Variety Statute (IP Osgoode)

EU: German Federal Supreme Court referral to ECJ concerning embryonic stem cells and the Biotech Directive (EPLAW)

EU: Data exclusivity and food claims in Europe – Commission authorises health claim on the effect of water-soluble tomato concentrate on platelet aggregation and grants protection of proprietary data under Regulation (EC) No 1924/2006 (IPKat)

France: Pharma trade marks under threat – Senate and National Assembly approve law that would allow generic companies to copy shape and colour of branded pharmaceuticals (Managing IP)

India: Jurassic Park to Bayh Dole: Crichton makes an effortless leap from science fiction to policy recommendation (Spicy IP)

Sweden: Seeking preliminary injunction for pharmaceutical patent infringement in Sweden (EPLAW)

Netherlands: Hague District Court invalidates Dutch part of three European patents of Merial concerning Post-Weaning Multisystemic Wasting Syndrome: Intervet v Merial (EPLAW)

US: Declaratory judgment of non infringement and invalidity complaint filed with District Court Columbia: Syngenta Seeds, Inc. v. Bayer Bioscience N.V. (Patent Docs)

US: Science Progress article examines impact of gene patents on research (Patent Docs)

US: Gene patenting debate continues: round three – Science Friday public debate on National Public Radio (Patent Docs)

 
Products

Circadin (Melatonin) – UK: IPO refuses SPC for Circadin (SPC blog)

Dovonex (Calcipoltriol) – UK: EWCA upholds Leo Pharma’s patent: LEO Pharma A/S and LEO Laboratories Limited v. Sandoz Limited (EPLAW)

Fuzeon (Enfuvirtide) – US: If there are no sources of proof in the E D of Texas, expect to transferred: In re Hoffman-La Roche Inc (Filewrapper)

Gemzar (Gemcitabine) – US: Eli Lilly appeals from grant of partial summary judgment finding certain claims invalid for double patenting: Sun Pharma v Eli Lilly (PATracer)

Gemzar (Gemcitabine) – US: Eli Lilly files patent infringement complaint against APP Pharmaceuticals following Para IV challenge (Patent Docs)

Kaletra (Lopinavir, Ritonavir) – US: District Court decision acts to preserve 180 day exclusivity eligibility; an interesting solution around a forfeiture catch-22 (FDA Law Blog)

Nuvigil (Armodafinil) – US: Cephalon files patent infringement suits against Mylan and Actavis following Para IV challenge (Patent Docs)

Prevacid (Lansoprazole) – US: Takeda and Ethylpharm appeal judgment finding Teva’s ANDA filing for generic Prevacid does not infringe: Takeda v Teva (PATracer)

Reminyl (Galantamine) – EU: EWCA reference to ECJ in SPC case Generics v Synaptech on Curia at last (SPC blog)

Roundup Ready 1 soybean – US: Monsanto to allow farmers to continue to grow Roundup Ready 1 soybeans after patent expires in 2014 (IPKat)

Singulair (Montelukast) – US: PTO reverses tentative rejection of key claims in Singulair patent (GenericsWeb)

Tamiflu (Oseltamivir) – China/India: While India copies, the Chinese invent… the traditional way (Spicy IP)

TOBI (Tobramycin) – US: Seattle Children’s Hospital files patent infringement complaint against Teva in response to its Para IV challenge (Patent Docs)

Tygacil (Tigecycline)– US: Wyeth files patent infringement complaint against Sandoz in response to Para IV challenge (Patent Docs)

Vytorin (Ezetimibe, Simvastatin) – US: Schering files patent infringement suit against Mylan over generic Vytorin ANDA (SmartBrief)

Zyprexa (Olanzapine) – UK: Court of Appeal upholds Justice Floyd’s decision finding Olanzapine patent valid: Dr Reddy’s Laboratories v Eli Lilly (EPLAW) (IPKat) (Managing IP) (PatLit) (GenericsWeb)

 

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: